search
Back to results

Safety, Reactogenicity and Immunogenicity of an H5N1 VLP

Primary Purpose

Pandemic Influenza

Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
H5N1 VLP Vaccine
Placebo
Sponsored by
Novavax
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Pandemic Influenza

Eligibility Criteria

18 Years - 40 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. Male or female 18 to 40 years of age at the time of the vaccination.
  2. Subjects who the investigator believes can and will comply with the requirements of the protocol (e.g., return for follow-up visits and completion of the data collection tool).
  3. Available by telephone.
  4. Free of obvious health problems as established by medical history and clinical examination before entering the study.
  5. If subject is of childbearing potential, she must be abstinent or have used adequate contraceptive precautions (e.g., intrauterine contraceptive device; oral contraceptives or other equivalent hormonal contraception) for 30 days prior to vaccination. She must also have a negative pregnancy test at study entry and must agree to continue such precautions for two months after completion of vaccination.
  6. Must provide written, informed consent.

Exclusion Criteria:

  1. Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the administration of the study vaccine, or planned use during the study period.
  2. Has received any other licensed vaccines within 4 weeks prior to enrollment in this study.
  3. Has received any influenza vaccine within the prior 12 month period.
  4. Has received any investigational vaccine designed for protection against avian influenza.
  5. Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the administration of the study vaccine. The use of inhaled and nasal steroids will be permitted.
  6. Any medically diagnosed or suspected immunodeficient condition based on medical history and physical examination.
  7. Administration of immunoglobulins and/or any blood products within the three months preceding the administration of the study vaccine or during the study.
  8. Acute disease at the time of enrollment. Acute disease is defined as the presence of a moderate or severe illness with or without fever ≥ 100.5º F.
  9. Acute clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or laboratory screening tests.
  10. Major congenital defects or serious chronic illness.
  11. History of any neurological disorders or seizures, with the exception of febrile seizures during childhood.

Sites / Locations

  • Healthcare Discoveries, Inc.

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Experimental

Experimental

Placebo Comparator

Arm Label

Low dose H5N1 VLP Vaccine

Mid dose H5N1 VLP Vaccine

High dose H5N1 VLP Vaccine

Placebo

Arm Description

Outcomes

Primary Outcome Measures

Safety and reactogenicity of H5N1 VLP Vaccine

Secondary Outcome Measures

Immunogenicity of H5N1 VLP Influenza vaccine

Full Information

First Posted
August 20, 2007
Last Updated
June 12, 2013
Sponsor
Novavax
search

1. Study Identification

Unique Protocol Identification Number
NCT00519389
Brief Title
Safety, Reactogenicity and Immunogenicity of an H5N1 VLP
Official Title
A Phase I/IIa Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of an H5N1 Virus-Like Particle (VLP) Influenza Vaccine (Recombinant)
Study Type
Interventional

2. Study Status

Record Verification Date
March 2012
Overall Recruitment Status
Completed
Study Start Date
July 2007 (undefined)
Primary Completion Date
November 2008 (Actual)
Study Completion Date
November 2008 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Novavax

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This is a Phase I/IIa randomized, double-blind, placebo-controlled study to evaluate the safety, reactogenicity, and immunogenicity of 3 potencies (dosages) of H5N1 VLP vaccine or placebo in healthy adults 18 to 40 years of age.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pandemic Influenza

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 1, Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
230 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Low dose H5N1 VLP Vaccine
Arm Type
Experimental
Arm Title
Mid dose H5N1 VLP Vaccine
Arm Type
Experimental
Arm Title
High dose H5N1 VLP Vaccine
Arm Type
Experimental
Arm Title
Placebo
Arm Type
Placebo Comparator
Intervention Type
Biological
Intervention Name(s)
H5N1 VLP Vaccine
Intervention Description
Two doses - Day 0 & Day 28
Intervention Type
Biological
Intervention Name(s)
Placebo
Intervention Description
Two doses - Day 0 & Day 28
Primary Outcome Measure Information:
Title
Safety and reactogenicity of H5N1 VLP Vaccine
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Immunogenicity of H5N1 VLP Influenza vaccine
Time Frame
6 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Male or female 18 to 40 years of age at the time of the vaccination. Subjects who the investigator believes can and will comply with the requirements of the protocol (e.g., return for follow-up visits and completion of the data collection tool). Available by telephone. Free of obvious health problems as established by medical history and clinical examination before entering the study. If subject is of childbearing potential, she must be abstinent or have used adequate contraceptive precautions (e.g., intrauterine contraceptive device; oral contraceptives or other equivalent hormonal contraception) for 30 days prior to vaccination. She must also have a negative pregnancy test at study entry and must agree to continue such precautions for two months after completion of vaccination. Must provide written, informed consent. Exclusion Criteria: Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the administration of the study vaccine, or planned use during the study period. Has received any other licensed vaccines within 4 weeks prior to enrollment in this study. Has received any influenza vaccine within the prior 12 month period. Has received any investigational vaccine designed for protection against avian influenza. Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the administration of the study vaccine. The use of inhaled and nasal steroids will be permitted. Any medically diagnosed or suspected immunodeficient condition based on medical history and physical examination. Administration of immunoglobulins and/or any blood products within the three months preceding the administration of the study vaccine or during the study. Acute disease at the time of enrollment. Acute disease is defined as the presence of a moderate or severe illness with or without fever ≥ 100.5º F. Acute clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or laboratory screening tests. Major congenital defects or serious chronic illness. History of any neurological disorders or seizures, with the exception of febrile seizures during childhood.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
George Atiee, M.D.
Organizational Affiliation
Healthcare Discoveries, Inc.
Official's Role
Principal Investigator
Facility Information:
Facility Name
Healthcare Discoveries, Inc.
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78209
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Safety, Reactogenicity and Immunogenicity of an H5N1 VLP

We'll reach out to this number within 24 hrs